What is Clairity?
Clairity operates at the intersection of artificial intelligence and oncology, providing advanced solutions designed to enhance the capabilities of healthcare providers. By focusing on early detection and personalized care, the company addresses critical gaps in cancer diagnostics and treatment planning. Its core technology utilizes sophisticated algorithms to extract actionable insights from complex imaging data, thereby reducing diagnostic disparities and improving patient outcomes.
The company's market position is bolstered by its commitment to evidence-based medicine, with solutions informed by extensive research from leading medical institutions. Clairity is not merely a software provider but a strategic partner in the precision medicine ecosystem, empowering both clinicians and patients with the data necessary to make informed, high-stakes health decisions.
How much funding has Clairity raised?
Clairity has raised a total of $43M across 1 funding round:
Series B
$43M
Series B (2025): $43M with participation from ACE, Breast Cancer Research Foundation, and Santé Ventures
Key Investors in Clairity
ACE
ACE Company is a multi-stage private equity and venture capital group specializing in Secondaries, Buyouts, and Ventures, with a total of 1.8 billion in assets.
Breast Cancer Research Foundation
An independent, not-for-profit organization that has raised $569.4 million to support clinical and transnational research on breast cancer at medical institutions globally.
Santé Ventures
A privately held investment firm managing over $1 billion in capital, focusing on innovative healthcare and technology companies within the Biotech, Medtech, and Healthtech sectors.
What's next for Clairity?
With the successful closure of this funding round, Clairity is poised to scale its operations and deepen its integration within global medical networks. The strategic roadmap likely involves enhancing the robustness of its AI models through larger datasets and pursuing regulatory milestones that will facilitate wider adoption in clinical settings.
Furthermore, the company is expected to focus on operational efficiency and market penetration, utilizing its recent capital to strengthen its commercial infrastructure. As Clairity continues to refine its diagnostic accuracy, it remains a key player to watch in the healthtech sector, particularly as the industry shifts toward more personalized, data-centric care models.
